Global stocks: Two buy and one sell

Published December 4, 2019

We took a trip to India last week and wrote about a few heavyweights that were driving the Indian stock markets to new highs. We return back to the US markets and will write about three stocks taken from the Stock selection category that Investtech provides. You can filter through some given parameters and get your own customized list of stocks. What we have today is two buy and one sell.

Merck & Co Inc (MRK.US500) Close: 87.38

Merck & Co. Inc. is inside a rising trend channel in the medium term. Rising trends show that investors over time have bought the stock at higher prices and indicate good development for the company. Since its bottom in early 2018, the stock has gone up consistently and has gained over 63 per cent.

Merck & Co. Inc. is one of the world's largest pharmaceutical companies and recently the stock gave a positive signal from a rectangle formation at the break up through the resistance at 86.93 dollars. Further rise to 94.03 or more is signalled. The stock has marginally broken up through the resistance at 86.70 dollars. An established break predicts a further rise. There is support around 80 dollars.

The short term momentum indicator RSI is above 70 after a good price increase the past weeks. The short term volume balance indicator is also positive which indicates that more and more investors are now interested in buying the stock. The stock has strong positive momentum and further increase is indicated.

Investtech's outlook (one to six months): Positive

 

Incyte Corp. (INCY.US500) Close: 94.10

Investors have paid higher prices over time to buy Incyte Corp. and the stock is in a rising trend channel in the short, medium and long term. Rising trends indicate that the company experiences positive development and that buy interest among investors is increasing.

The healthcare and biotech company has recently given a buy signal by closing above the resistance of 88 dollars and has initiated a buy through a breakout from the ceiling of a rectangle formation both in the medium and long term charts. Further rise to 108 dollars or more is indicated. In case of any reaction on the downside, there is support around 88 and 82 dollars respectively.

Positive volume balance shows that volume is higher on days with rising prices than days with falling prices. This indicates increasing optimism among investors. RSI is above 70 after a good price increase the past weeks. The stock has strong positive momentum and further increase is indicated.

Investtech's outlook (one to six months): Positive

 

IBM (IBM.US500) Close: 132.12

IBM is within an approximate horizontal trend channel in the medium term and is inside a downward trend channel both in the short and long term charts. The stock has marginally closed below the neckline of the head and shoulders formation. An established break below yesterday's close, preferably on higher volume, will initiate a new sell signal.

The stock has some support around 130 dollars, but long term investors seem to be impatient as the volume balance indicator is turning down. Further down the line, next support is around 108 dollars. The stock has resistance around 145 dollars.

Investtech's outlook (one to six months): Negative

The analyses are based on closing price as per December 04, 2019. 

These instruments are traded in currency based on the Exchange or country they are listed on.

Kirjoittaja

Kiran R. Shroff
Analyst
Investtech

"Investtech analysoi markkinoiden psykologiaa ja antaa konkreettisia kaupankäyntisuosituksia päivittäin."

Espen Grønstad
Partner & Senior Advisor - Investtech
 


Investtech ei takaa analyysien tarkkuutta tai kattavuutta. Kaikkien analyysien tuottamien neuvojen ja signaalien käyttäminen on täysin käyttäjän vastuulla. Investtech ei vastaa mistään tappioista, jotka saattavat syntyä Investtechin analyysien käytön seurauksena. Mahdollisten eturistiriitojen yksityiskohdat mainitaan aina sijoitusneuvon yhteydessä. Lisätietoja Investtechin analyyseistä löytyy täältä disclaimer.


Investtech ei takaa analyysien tarkkuutta tai kattavuutta. Kaikkien analyysien tuottamien neuvojen ja signaalien käyttäminen on täysin käyttäjän vastuulla. Investtech ei vastaa mistään tappioista, jotka saattavat syntyä Investtechin analyysien käytön seurauksena. Mahdollisten eturistiriitojen yksityiskohdat mainitaan aina sijoitusneuvon yhteydessä. Lisätietoja Investtechin analyyseistä löytyy täältä disclaimer.

Titlex

OK
+

Samtykke

Vi bruger cookies for at give dig en bedre brugeroplevelse. Hvis du fortsætter med at bruge hjemmesiden, accepterer du dette. For yderligere detaljer klik her.

Vores brug af cookies

Når du bruger vores hjemmeside, gemmer vi en cookie på din enhed. Cookien bruges til at genkende din enhed, så dine indstillinger fungerer, når du bruger vores hjemmesider. De oplysninger, der opbevares, er fuldstændig anonymiserede. Cookies slettes automatisk efter en vis tid.

Nødvendige cookies

Investtech bruger cookies til at sikre grundlæggende funktioner som sidenavigation og sprogvalg. Uden sådanne cookies fungerer hjemmesiden ikke, som den skal. Du kan derfor ikke tage forbehold mod disse. Hvis du stadig ønsker at deaktivere sådanne cookies, kan du gøre det i dine browserindstillinger. I sektionen Cookies tilføj denne hjemmeside til listen over websteder, der ikke har tilladelse til at gemme cookies på din enhed.

Cookies fra Google

Vi bruger tjenester fra Google Analytics og Google AdWords. Disse registrerer cookies på din enhed, når du besøger vores hjemmeside. Google registrerer din IP-adresse for at føre statistik over brugeraktivitet på hjemmesiden. IP-adressen er anonymiseret, så vi ikke har mulighed for at knytte aktiviteterne til en bestemt person. Vi bruger disse statistikker til at kunne tilbyde mere interessant indhold på hjemmesiden og til konstant at forbedre os. Google AdWords indsamler data, så vores annoncering på andre hjemmesider giver bedre resultater. Vi kan ikke spore enkeltpersoners data.

Tillad cookies fra Google